Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DABIGATRAN ETEXILATE Cause Hyperthyroidism? 16 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Hyperthyroidism have been filed in association with DABIGATRAN ETEXILATE (dabigatran etexilate). This represents 0.0% of all adverse event reports for DABIGATRAN ETEXILATE.

16
Reports of Hyperthyroidism with DABIGATRAN ETEXILATE
0.0%
of all DABIGATRAN ETEXILATE reports
0
Deaths
12
Hospitalizations

How Dangerous Is Hyperthyroidism From DABIGATRAN ETEXILATE?

Of the 16 reports, 12 (75.0%) required hospitalization, and 5 (31.3%) were considered life-threatening.

Is Hyperthyroidism Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DABIGATRAN ETEXILATE. However, 16 reports have been filed with the FAERS database.

What Other Side Effects Does DABIGATRAN ETEXILATE Cause?

Gastrointestinal haemorrhage (4,081) Cerebrovascular accident (2,175) Fall (1,786) Ischaemic stroke (1,581) Anaemia (1,412) Haemorrhage (1,324) Death (1,025) Rectal haemorrhage (964) Cerebral haemorrhage (946) Upper gastrointestinal haemorrhage (861)

What Other Drugs Cause Hyperthyroidism?

LEVOTHYROXINE (1,681) AMIODARONE (1,410) NIVOLUMAB (934) PEMBROLIZUMAB (780) IPILIMUMAB (525) CARBOPLATIN (432) ATEZOLIZUMAB (416) PACLITAXEL (261) ALEMTUZUMAB (236) LENVATINIB (231)

Which DABIGATRAN ETEXILATE Alternatives Have Lower Hyperthyroidism Risk?

DABIGATRAN ETEXILATE vs DABRAFENIB DABIGATRAN ETEXILATE vs DABRAFENIB\TRAMETINIB DABIGATRAN ETEXILATE vs DACARBAZINE DABIGATRAN ETEXILATE vs DACLATASVIR DABIGATRAN ETEXILATE vs DACLIZUMAB

Related Pages

DABIGATRAN ETEXILATE Full Profile All Hyperthyroidism Reports All Drugs Causing Hyperthyroidism DABIGATRAN ETEXILATE Demographics